St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY;
Blood. 2013 Oct 3;122(14):2390-401. doi: 10.1182/blood-2013-01-480814. Epub 2013 Aug 20.
We report a molecular study of the two known patients with autosomal recessive, partial interferon-γ receptor (IFN-γR)2 deficiency (homozygous for mutations R114C and G227R), and three novel, unrelated children, homozygous for S124F (P1) and G141R (P2 and P3). IFN-γR2 levels on the surface of the three latter patients' cells are slightly lower than those on control cells. The patients' cells also display impaired, but not abolished, response to IFN-γ. Moreover, the R114C, S124F, G141R and G227R IFNGR2 hypomorphic alleles all encode misfolded proteins with abnormal N-glycosylation. The mutants are largely retained in the endoplasmic reticulum, although a small proportion reach and function at the cell surface. Strikingly, the IFN-γ response of the patients' cells is enhanced by chemical modifiers of N-glycosylation, as previously shown for patients with gain-of-glysosylation T168N and misfolding 382-387dup null mutations. All four in-frame IFNGR2 hypomorphic mutant alleles encoding surface-expressed receptors are thus deleterious by a mechanism involving abnormal N-glycosylation and misfolding of the IFN-γR2 protein. The diagnosis of partial IFN-γR2 deficiency is clinically useful, as affected patients should be treated with IFN-γ, [corrected] unlike patients with complete IFN-γR2 deficiency. Moreover, inhibitors of glycosylation might be beneficial in patients with complete or partial IFN-γR2 deficiency due to misfolding or gain-of-glycosylation receptors.
我们报告了两名常染色体隐性、部分干扰素-γ受体(IFN-γR)2 缺陷(杂合突变 R114C 和 G227R)患者的分子研究,并对三名新的、无关联的患儿(P1 为 S124F,P2 和 P3 为 G141R)进行了研究。后三名患者细胞表面的 IFN-γR2 水平略低于对照细胞。这些患者的细胞对 IFN-γ的反应也存在缺陷,但并未完全丧失。此外,R114C、S124F、G141R 和 G227R IFNGR2 低功能等位基因均编码具有异常 N-糖基化的错误折叠蛋白。突变体主要在内质网中保留,尽管一小部分到达并在细胞表面发挥功能。引人注目的是,患者细胞的 IFN-γ反应可被 N-糖基化化学修饰剂增强,这与获得糖基化 T168N 和错误折叠 382-387dup 缺失突变患者的情况先前一致。所有四种框内 IFNGR2 低功能突变等位基因编码表达表面受体的受体均通过涉及 IFN-γR2 蛋白异常 N-糖基化和错误折叠的机制产生有害影响。部分 IFN-γR2 缺陷的诊断在临床上是有用的,因为受影响的患者应接受 IFN-γ治疗,[纠正]不像完全 IFN-γR2 缺陷的患者。此外,由于错误折叠或获得糖基化受体,糖基化抑制剂可能对完全或部分 IFN-γR2 缺陷的患者有益。